Interaction of Glycemic Control and Statin Use on Diabetes-Tuberculosis Treatment Outcome: A Nested Case-Control Study.
Xiangrui Meng, Huiqiu Zheng, Jian Du, Xuemei Wang, Yanling Wang, Jing Hu, Jing Zhao, Qianqian Du, Yulong Gao
Author Information
Xiangrui Meng: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Huiqiu Zheng: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Jian Du: Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing 101149, China. ORCID
Xuemei Wang: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Yanling Wang: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Jing Hu: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Jing Zhao: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Qianqian Du: Center for Data Science in Health and Medicine, School of Public Health, Inner Mongolia Medical University, Hohhot 010110, China. ORCID
Yulong Gao: Department of Infectious Disease Control and Prevention, Inner Mongolia Center for Disease Control and Prevention, Hohhot 010031, China. ORCID
This study aims to explore the interaction of glycemic control and statin use on the treatment outcomes of pulmonary tuberculosis-diabetes comorbidity (PTB-DM) patients. A nested case-control study was conducted in a tuberculosis patients' cohort. We defined cases as patients who experienced unfavorable outcomes. Glycemic control was estimated at the baseline. Statin use was obtained from medical records. The multivariate logistic regression models were developed, and the interaction table invented by Andersson was adopted to analyze the interaction of glycemic control and statin use on treatment outcomes. A total of 2,047 patients were included in this study. There was a significant interaction between glycemic control and statin use on the treatment outcomes. Patients with good glycemic control and no statin use (OR = 0.464, 95% CI: 0.360-0.623) had a lower risk of unfavorable outcomes than those with poor glycemic control and statin use (OR = 0.604, 95% CI: 0.401-0.734). Patients with good glycemic control and statin use had the lowest risk of unfavorable outcomes (OR = 0.394, 95% CI: 0.264-0.521). Glycemic control in diabetes-tuberculosis treatment should be paid considerable attention. Patients can benefit from statin use even if they have poor glycemic control. Patients with good glycemic control and statin use can have the best outcomes.
